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Role of dietary protein and blood pressure in the progression of renal
disease. The Modification of Diet in Renal Disease (MDRD) Study
examined the effect of two interventions, reduction of dietary protein and
control of blood pressure below the usual recommended level, on the
progression of chronic renal disease. Patients in Study A (N = 585), GFR
of 25 to 55 mI/mm, were randomized to a group following a usual or low
protein diet (1.3 or 0.58 glkg body wt/day) and maintained at a usual (107
mm Hg) or low (92 mm Hg) mean arterial pressure. Patients in Study B
(N = 255), GFR 13 to 24 ml/min, were randomized to a group following
a low protein diet or a very low protein diet (0.28 g/kg body wt/day
supplemented with a mixture of keto acids and amino acids), and
maintained at a usual or low blood pressure level. During the first four
months of follow-up in Study A, GFR declined at a faster rate in patients
assigned a low protein diet or low blood pressure goal. The "terminal"
GFR slope (measured from the fourth month of follow-up and projected
to 3 years of follow-up) was 28% less, as a mean, in patients in the low
protein group versus those on the usual protein diet (P = 0.009). Also, the
low blood pressure group showed a significantly (P = 0.006) slower
progression of renal disease (29%) than the usual blood pressure group.
The effects of low blood pressure on the GFR decline were significantly
related to the level of proteinuria during the baseline period. The results
of Study B strongly suggest beneficial effects of the very low protein diet
on renal function in patients with a GFR less than 25 mI/mm.
Chronic renal disease, when untreated, is characterized by a
progressive and usually irreversible decline in glomerular filtra-
tion rate (GFR). The sustained decline in GFR is most likely
mediated by several factors acting alone or in combination.
Potential risk factors that may contribute to the progression of
chronic renal disease include systemic hypertension, proteinuria,
hyperlipidemia, high protein and/or phosphorus intake, and con-
ditions that promote clotting or infiltration of the renal paren-
chyma by immune cells [1]. Numerous studies support the concept
that dietary protein restriction and control of blood pressure delay
the progression of renal disease in laboratory animals [2, 3].
Studies in humans [4—10] have suggested that restriction of
dietary protein is beneficial, particularly in patients with advanced
renal insufficiency, although some studies are difficult to interpret
because of deficiencies in their design or because of the method-
ology used to assess the progression of the renal disease. In
addition, few studies have examined the effect of two levels of
adequately controlled blood pressure, one at the usual recom-
mended level and one below it, on the progression of renal disease
in humans.
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The Modification of Diet in Renal Disease Study
The Modification of Diet in Renal Disease (MDRD) Study
tested the hypothesis that two separate interventions, reduction of
dietary protein and control of blood pressure below the usual
recommended level, retard the progression of renal disease [11].
The MDRD was a multi-center trial conducted in 840 patients
with chronic renal disease of diverse etiology. There were two
randomized studies. In Study A, 585 patients with a baseline GFR
of 25 to 55 ml/min/1.73 m2 were randomized to a group consuming
a usual or a low-protein diet (1.3 or 0.58 g/kg/body wt/day) and
maintained at a usual or low mean arterial pressure (107 or 92 mm
Hg). In Study B, 255 patients with a GFR of 13 to 24 ml/min/1.73
m2 were randomly assigned to a group consuming a low or a very
low (0.28 g/kg/day) protein diet (the latter supplemented with a
mixture of keto acids and amino acids) and maintained at a usual
or low blood pressure level [11]. The average follow-up of the
patients was 2,2 years. The patients were evaluated at monthly
intervals.
In the MDRD study, substantial differences in the rate of GFR
decline were evident in patients with diverse renal diseases.
Patients with glomerular disease and proteinuria in excess of 3
g/day had faster declines in GFR than patients with glomerular
disease and proteinuria less than 1 g/day [11]. Patients with
polycystic kidney disease had more rapid declines in GFR than
those with glomerular disease and no proteinuria or those with
other diagnoses (interstitial disease, etc.). Also, males "pro-
gressed" faster than females and the loss of GFR versus time was
greater in blacks than in whites [11].
Dietary protein restriction
Adherence to protein goals was assessed monthly based on urea
nitrogen excretion in 24-hour urine samples and bimonthly from
three-day food records. In Study A, patients assigned to the usual
protein intake group ingested 1.12 g protein/kg body wt/day
during follow-up instead of the prescribed 1.3 g/kg body wt/day.
Patients assigned to the low protein diet group ingested 0.73 g
protein/kg body wt/day instead of the prescribed 0.58 g protein/kg
body wt/day. Nevertheless, there was a significant separation in
mean protein intake between the two dietary groups, a difference
that persisted throughout the duration of the study.
During the first four months of follow-up in Study A, GFR
declined at a faster rate in the group of patients assigned a
low-protein diet (see Table 1). Thereafter, the decline was slower
in this group (Table 1). The "terminal" GFR slope (measured
from the fourth month of follow-up and projected to 3 years of
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Table 1. Mean rate of decline in glomerular filtration rate in Study A




Usual blood Low blood
pressure pressure
Baseline to 4 months
Usual protein
Low protein
From 4 months to end of study
Usual protein
Low protein
milliliters per minute per 4 months
1.2 2.4
2.6 4.3
milliliters per minute per year
4.5 3.3
3.3 2.3
There were significant effects of the dietary (protein) and blood
pressure interventions from the baseline visit to the fourth month of
follow-up (P = 0.004 and P = 0.010, respectively) and from the fourth
month to the end of follow-up (P = 0.009 and P = 0.006, respectively).
(Modified and used with permission, from: KLAHR 5, LEVEY AS, BECK GJ,
CAGGIULA AW, HUNSICKER L, KUSEK JW, STRIKER G, MDRD STUDY
GROUP: The effects of dietary protein restriction and blood pressure
control on the progression of chronic renal disease. N Engl J Med
330:877—884, 1994.)
follow-up) was 28% less, as a mean, in patients randomized to the
low protein diet group compared to those prescribed the usual
protein diet (P = 0.009). Also, patients randomized to the low
protein diet group had significantly smaller increases in the level
of protein excretion in the urine compared to those assigned to
follow a usual protein diet. Because proteinuria appears to have a
pathogenetic role in the progression of renal disease [12J, the
effect of the low protein diet to delay the increase in proteinuria
suggests a benefit of this intervention in patients with progressive
renal disease.
In principle, because of the diverging effects of the low protein
diet on the GFR decline before and after four months of
follow-up, the net effect on the level of GFR in the low protein
diet group compared to the usual protein diet group would
depend on the duration of follow-up. The GFR value projected
from baseline to three years of follow-up was numerically higher
in patients randomized to the low-protien diet compared to those
on the usual protein diet. However, this difference in GFR did not
achieve statistical significance (P = 0.30). In fact, according to the
model derived from observed and projected results, during a short
follow-up period, a detrimental effect of the intervention would be
observed, while after a long follow-up period, a beneficial effect
would be observed. Among patients with more rapidly declining
GFRs over the duration of the study, the beneficial effect of
protein restriction would be observed in a relatively shorter
follow-up interval, Indeed, the comparison of the distribution of
GFR slopes in patients assigned to the usual versus the low
protein diet suggests a beneficial effect of the low protein diet in
the subgroup of patients with more rapid GFR decline. A
detrimental effect of the low protein diet on the level of GFR
occurred in the subgroup of patients with the slowest decline in
GFR. However, given the overall mean rate of decline in GFR
observed in Study A patients, we estimated that an additional
three years or more of follow-up would have been required to
detect a difference in the mean decline in GFR from baseline to
the end of the study between the two diet groups.
Study B patients assigned the very low protein diet ingested 0.47
g of protein/kg body wt/day during follow-up instead of the 0.28 g
Table 2. Mean rate of decline in glomerular filtration rate from
baseline to end of the study in patients in Study B
Diet
Decline in GFR
milliliters per minute per year
Usual blood pressure Low blood pressure
Low protein 4.9 3.9
Very low protein 3.6 3.5
The mean rates of decline in GFR, which were calculated according to
the single slope informative model, were of borderline significant differ-
ence between the two protein diet groups (P = 0.07) and were not
significant between the blood pressure groups. (Modified and used with
permission, from: KLAHR 5, LEVEY AS, BECK GJ, CAGGIULA AW,
HUNSICKER L, KUSEK JW, STRIKER G, MDRD STUDY GROUP: The effects
of dietary protein restriction and blood pressure control on the progres-
sion of chronic renal disease. N EngI J Med 330:877—884, 1994.)
prescribed. However, their protein intake was significantly less
than the protein intake (0.73 g/kg body wt/day) of the group
following the low protein diet in this study. The mean decline in
GFR in Study B patients appeared relatively constant over the
entire follow-up period [11]. Correlational analysis of the rela-
tionship of renal function to protein intake in Study B strongly
suggests beneficial effects of a low-protein diet on the progression
of renal disease in patients with GFR less than 25 ml/min/1.73 m2
(Table 2). These effects include a slowing in the decline in GFR
and a reduced risk of renal failure or death. In this study, each
reduction in protein intake of 0.2 glkg/day was associated with a
slowing of the GFR decline by 1.15 ml/min/year (approximately
30% of the mean GER decline) and by an approximate halving of
the relative risk of death or renal failure.
Blood pressure control
Patients in Study A, but not in Study B, randomized to the
group with the low blood pressure goal had a faster mean decline
in GFR during the first four months of follow-up (Table 1) and a
slower decline thereafter (Table 1), compared to patients assigned
the usual blood pressure goal [11]. This marked decrement in
GFR during the first four months may be due to a hemodynamic
effect of the low blood pressure intervention: single nephron GFR
may have decreased without a loss of nephrons and hence without
progression of the renal disease. When the effect of the blood
pressure intervention was analyzed utilizing the four-month fol-
low-up visit as the initial point for the calculation of the GFR
slope projected to three years, a significantly slower progression of
the renal disease (29%) was observed in the low blood pressure
group compared to the usual blood pressure group (P 0.006).
The beneficial effects of the low blood pressure goal on GFR
decline were significantly related to baseline protein excretion
after the first four months of follow-up. Consequently, the mag-
nitude of the protein excretion at baseline appeared to determine
the onset of the slowing of that decline in GFR attributable to
blood pressure control. In patients with protein excretion greater
than 3 g/day, the benefit of the low blood pressure intervention
was observed after about one year of follow-up. In contrast, in
patients with protein excretion between 1 and 3 g/day the benefit
of the low blood pressure goal in slowing the GFR decline did not
become clear until after an average of two years of follow-up. An
even longer follow-up would have been necessary to determine
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whether the low blood pressure goal is beneficial in patients with
baseline proteinuria of 0.25 to 1.0 g/day.
In Study B, there was no appreciable difference in the rate of
decline in GFR between the two blood pressure groups (Table 2).
The difference in mean arterial pressure between the usual and
low blood pressure groups during the follow-up period was 4.7
mm Hg (P < 0.001) in both Studies A and B. This difference was
smaller than the targeted difference of 15 mm Hg. Nevertheless,
this difference in blood pressure had a significant effect in slowing
the progression of renal disease in patients with protein excretion
in excess of I glday. The finding of a considerably slower loss of
renal function in the patients with proteinuria in excess of 1 g
randomized to the low blood pressure group indicates that the
currently recommended levels of blood pressure control in pa-
tients with chronic renal disease and proteinuria may not be
appropriate. Based on the MDRD findings, mean arterial pres-
sure should be lowered to 92 mm Hg or less in patients with
proteinuria in excess of 1 g/day. This would be the equivalent of
blood pressures of 126/75 or 132/72 mm Hg.
Has there been a decrease in the rate of progression of renal
disease in the last decade?
The overall rate of GFR loss in the MDRD study was less than
expected. It averaged 4.2 ml/min per year. This mean value is less
than the values utilized in the mid-1980s to calculate the sample
size for the MDRD study (loss of GFR of 6 ml/min per year).
Several potential explanations for this change include: (1) The
rate of loss of GFR in patients with renal disease has decreased in
the last decade due to better management of blood pressure and
widespread use of dietary protein restriction. (2) The close
follow-up and supervision ("clinic effect") that these patients
received during the MDRD trial ameliorated the progression of
renal disease when compared to historical controls of the mid-
eighties. (3) The increasing use in the last decade of ACE
inhibitors to treat hypertension in patients with renal disease may
have slowed the rate of progression of renal disease.
Has the widespread use of ACE inhibitors masked the benefits
of protein restriction on the progression of renal disease?
The increased use of ACE inhibitors in medical practice in
recent years may have masked to some extent the effect of protein
restriction on the rate of loss of GFR. Dietary protein has been
shown to regulate both the synthesis and release of renin [13].
Renal renin mRNA was reported to be higher in rats fed a high
protein diet (50%) than in rats fed a standard rat chow (20%
protein). A lower protein intake (6%) decreased the activity of
renal renin mRNA in rats [13].
Increases in dietary protein intake in humans have also been
found to be accompanied by a higher plasma renin activity and an
increased excretion of prostaglandin E2 and prostacyclin in the
urine of patients with glomerular disease [14]. The increased
excretion of eicosanoids in the urine of patients ingesting high-
protein diets suggests that augmented synthesis of metabolites of
arachidonic acid may mediate the increased release of renin in
such patients [14]. Protein intake has been shown to affect
eicosanoid synthesis in isolated glomeruli obtained from rats {15,
16]. Glomeruli obtained from rats fed a high protein diet pro-
duced significantly greater amounts of eicosanoids under basal
conditions than glomeruli from rats fed a low protein diet. Dietary
protein intake has also been found to modulate glomerular
production of eicosanoids in three models of experimental renal
disease in the rat: partial renal ablation, Heymann nephritis and
streptozotocin-induced diabetes mellitus [17, 18]. Administration
of an ACE inhibitor (enalapril) in vivo attenuated the protein-
induced augmentation in glomerular eicosanoid production [16].
In rats fed a high protein diet, inhibiting the synthesis of angio-
tensin II by administering an ACE inhibitor prevented the in-
creases in the activities of phospholipase A2 and cyclooxygenase
observed in untreated rats 16].
The observations described above suggest that increased pro-
tein intake augments renin-angiotensin production. Protein re-
striction appears to have the opposite effects. Hence a component
of the beneficial effect of dietary protein restriction on the
progression of renal disease may be attributable to decreased
angiotensin II production. If this is the case, the widespread use of
ACE inhibitors in recent years may have masked to some extent
the beneficial effects of protein restriction on the progression of
renal disease.
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